FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer

  • The FDA has removed the partial clinical hold placed on Alpine Immune Sciences Inc's ALPN NEON-2 trial of davoceticept (ALPN-202) in advanced malignancies.
  • Davoceticept is a first-in-class conditional CD28 costimulator and a dual checkpoint inhibitor.
  • The partial clinical hold was prompted by Alpine's report of patient death in the NEON-2 trial. 
  • The trial is evaluating davoceticept combined with Merck & Co Inc's MRK Keytruda (pembrolizumab).
  • Related: Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study
  • The FDA removed the hold after a review of the company's Complete Response, which included a comprehensive review of the davoceticept safety database and a revised investigator brochure and study protocol. 
  • The ongoing NEON-1 study of davoceticept as monotherapy was not subject to the hold.
  • Price Action: ALPN shares are up 2.53% at $8.51 during the premarket session on the last check Tuesday.
Posted In: BiotechNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!